|
|
|
Volumn 10, Issue 12, 2007, Pages 881-884
|
|
The impact of generic antiviral drugs
|
|
Author keywords
Antiretroviral therapy; Antiviral; Bioequivalence; Generic; HIV AIDS
|
|
Indexed keywords
ADEFOVIR;
ANTIRETROVIRUS AGENT;
ANTIVIRUS AGENT;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ENTECAVIR;
GENERIC DRUG;
INTEGRASE INHIBITOR;
LAMIVUDINE;
LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE;
OSELTAMIVIR;
PEDIMUNE;
PEGINTERFERON;
PROTEINASE INHIBITOR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
TELBIVUDINE;
TRIOMUNE BABY;
TRIOMUNE JUNIOR;
UNCLASSIFIED DRUG;
VIRADAY;
ZANAMIVIR;
AVIAN INFLUENZA;
DEVELOPING COUNTRY;
DRUG COST;
EPIDEMIC;
GOVERNMENT;
HEALTH CARE COST;
HEPATITIS C;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
REVIEW;
WORLD HEALTH ORGANIZATION;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
ANTIVIRAL AGENTS;
DRUGS, GENERIC;
HEPATITIS B;
HEPATITIS C;
HUMANS;
|
|
EID: 36549041471
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (2)
|
|
References (0)
|
